Melbourne, Victoria – Alcidion Group Ltd (ASX: ALC) (Company) today announces the resignation of Non-Executive Chairman Mr Ray Blight as Chairman, and the subsequent appointment of current Non Executive Director, Ms Rebecca Wilson as Chair.
Effective today, Ray voluntarily stepped down as Chairman of Alcidion. He will remain on Alcidion’s Board as a Non-Executive Director. Ray co-founded Alcidion in 2000 with Dr Malcolm Pradhan, and served as group CEO and Executive Chairman until its acquisitions of MKM Health and Patientrack in July 2019. In January 2019, Ray stepped down from executive duties and assumed the role of Non-Executive Chairman. Ray was instrumental in leading the acquisition of the MKM Health and Patientrack businesses and he has helped guide Alcidion to a place where it is excellently positioned to provide the enabling platform, as healthcare undergoes a digital transformation. He will continue to provide input and guidance in his Non Executive Director role.
Rebecca has more than 20 years’ experience working with public companies in health, technology and life sciences sectors, and has provided high-level advice to Boards and executive teams throughout her career on M&A transactions, issues management, investor and corporate relations, and capital raisings. As non-executive director at Alcidion, Rebecca assisted the company through its acquisitions of Oncall Systems, MKM Health and Patientrack, as well as the successful integration of the businesses. She has served on both the Remuneration, and Risk and Audit committees and been an active NED since her appointment two years ago, particularly around capital market strategy, investor relations, risk and governance.
Outgoing Chairman Ray Blight said, “I would like to firstly thank our shareholders for your support of Alcidion, many of whom have been here since we first listed. I would also like to thank our Board, management and staff for their tireless dedication to the ongoing growth of the business. Rebecca has proven herself to be a very effective Board member during her time at Alcidion, and her business leadership skills and extensive experience working with listed companies and investor networks is ideal as Alcidion enters its next phase of growth.”
Appointed Chair Rebecca Wilson said, “I’m honoured to have been asked to take on the role of Chair at Alcidion. This is a company that has effectively proven its technology platform and commercial expertise. We have a clear vision for growth, and I look forward to further supporting Kate and the team as we capitalise on the opportunity ahead of us, to deliver meaningful change in the healthcare industry and create shareholder value.”